Literature DB >> 18394025

Nitric oxide depresses connexin 43 after myocardial infarction in mice.

P E M Jackson1, Q P Feng, D L Jones.   

Abstract

AIMS: Heart failure (HF) is a major cause of death and morbidity. Connexin 43 (Cx43) content is reduced in the failing myocardium, but regulating factors have not been identified. In HF, inducible nitric oxide synthase (iNOS)-induced high levels of nitric oxide (NO) cause apoptosis and cardiac dysfunction. However, a direct iNOS-Cx43 link has not been demonstrated. We investigated this relationship in mice after myocardial infarction.
METHODS: Effects of myocardial infarction were evaluated 2 weeks after coronary artery ligation in wild-type C57BL/6 (WT) and iNOS(-/-) knockout mice. Myocardial Cx43 and Cx45 content were assessed by immunofluorescence confocal imaging and western blotting. Cardiac function was evaluated in anaesthetized mice using a micro pressure-tipped catheter inserted into the left ventricle.
RESULTS: Despite similar infarct size, deficiency in iNOS resulted in significantly lower plasma nitrate/nitrite levels, better haemodynamic performance and lower mortality 2 weeks after coronary ligation. Myocardial Cx43, but not Cx45, content was lower in WT mice following ligation. The reduction in Cx43 was less in iNOS(-/-) compared with WT mice. To assess the direct effect of NO on Cx43 expression, cultured neonatal mouse cardiomyocytes were employed. Incubation with the NO donor, S-nitroso-N-acetylpenicillamine, elicited a dose-dependent decrease in Cx43 content in cultured neonatal cardiomyocytes.
CONCLUSIONS: Increased NO production from iNOS depressed cardiac performance and contributed to the decreased myocardial Cx43 content 2 weeks after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394025     DOI: 10.1111/j.1748-1716.2008.01858.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  7 in total

Review 1.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 2.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

3.  Myocardial NOS activity and connexin-43 expression in untreated and omega-3 fatty acids-treated spontaneously hypertensive and hereditary hypertriglyceridemic rats.

Authors:  Jana Radosinska; Barbara Bacova; Iveta Bernatova; Jana Navarova; Anna Zhukovska; Angela Shysh; Ludmila Okruhlicova; Narcis Tribulova
Journal:  Mol Cell Biochem       Date:  2010-10-21       Impact factor: 3.396

4.  Interaction between connexin 43 and nitric oxide synthase in mice heart mitochondria.

Authors:  Mücella Kirca; Petra Kleinbongard; Daniel Soetkamp; Jacqueline Heger; Csaba Csonka; Péter Ferdinandy; Rainer Schulz
Journal:  J Cell Mol Med       Date:  2015-02-09       Impact factor: 5.310

Review 5.  Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient.

Authors:  Teerapat Nantsupawat; Wanwarang Wongcharoen; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cardiovasc Diabetol       Date:  2020-11-24       Impact factor: 9.951

6.  Function and Mechanism of Trimetazidine in Myocardial Infarction-Induced Myocardial Energy Metabolism Disorder Through the SIRT1-AMPK Pathway.

Authors:  Xiu-Ying Luo; Ze Zhong; Ai-Guo Chong; Wei-Wei Zhang; Xin-Dong Wu
Journal:  Front Physiol       Date:  2021-06-17       Impact factor: 4.566

7.  Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.

Authors:  Nattayaporn Apaijai; Kroekkiat Chinda; Siripong Palee; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.